X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Envirotainers Releye RAP container already approved by 10 airlines

Content Team by Content Team
8th April 2022
in Packaging & Logistic, Press Statements
Envirotainer introduces the RAP for the future - part of the Releye series

Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, announced a major milestone for its new Releye® RAP container. Launched just one month ago, 10 airlines around the world have now approved it for use.

Carriers across Asia, Europe, and the Middle East have authorised the container, including Cathay Pacific, China Airlines, EVA Air, Qatar Airlines, Saudi Airlines Cargo, Singapore Airlines, Swiss, TAP Air Portugal, Korean Airlines and Asiana Airlines. With their approval, Envirotainer can support the industry in meeting the ever growing need for large, temperature-controlled, high-quality and connected ULD solutions.

The Releye® RAP sets a new benchmark for temperature-controlled, five-pallet solutions. The largest of the new generation of Releye® containers, the RAP is the only one of its type in the world, combining big, optimized capacity with superior features.

Designed to meet the strictest requirements in pharmaceutical air freight, the integrated live monitoring enables a unique insight into product condition, location, and progress of the shipment.

With its increased efficiency and capacity, it reaches outstanding CO2 reductions per shipment, and is the future solution for secure cold chain shipments. All monitored and maintained with the new service, Control Tower. This offers a global team of operators to follow a shipment’s every move, ready to respond within minutes to any critical event.

The Releye® RAP is the second in a family of advanced temperature-controlled air freight containers Envirotainer is developing. It joins the three-pallet Releye® RLP launched in 2021. The foundation of the Releye® platform are the five pillars: control, monitoring, autonomy, value, and sustainability.

“We are extremely pleased to have 10 airline partners approve the new Releye® RAP container so far,” says Don Harrison, Head of Global Key Accounts, Airlines at Envirotainer. “They’re among the first to qualify the container for use on their fleets and will be able to offer medical shippers the very best in cold chain transportation.”

About Envirotainer AB

Envirotainer is the undisputed global market leader in secure cold-chain solutions?for intercontinental transport of pharmaceuticals. The company develops, manufactures, and offers leasing of innovative container solutions, including validation, support, and service, for pharma products that require a controlled environment. Thanks to a truly global presence with the world’s largest active container fleet, the most extensive network, and more than 35 years of industry expertise, Envirotainer is able to meet the customers’ need for innovative and reliable solutions – available from any location to any destination. The company operates through an open, global network of airlines, forwarders and couriers and the headquarters is located outside of Stockholm, Sweden.

Previous Post

Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

Next Post

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

Related Posts

ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Drug Development

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

4th March 2025
Next Post

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In